Susanne Singer
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
Apr 6, 2020Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Apr 6, 2020Clin Breast Cancer 2020; 20:439-447
Bekes Inga, Janni Wolfgang, Lato Krisztian, Kiechle Marion, Huober Jens, Dannecker Christian, Forstbauer Helmut, Rack Brigitte, Harbeck Nadia, Friedl Thomas W P, Singer Susanne, Eichler Martin, Fink Visnja
Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma-results of a multicenter study.
Renovanz M, Hickmann A, Nadji-Ohl M, Keric N, Weimann E, Wirtz C, Singer S, Ringel F, Coburger J. Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma-results of a multicenter study. Support Care Cancer 2020; 28:5165-5175.
Feb 14, 2020Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma-results of a multicenter study.
Feb 14, 2020Support Care Cancer 2020; 28:5165-5175
Renovanz Mirjam, Hickmann Anne-Katrin, Nadji-Ohl Minou, Keric Naureen, Weimann Elke, Wirtz Christian Rainer, Singer Susanne, Ringel Florian, Coburger Jan
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
Cámara R, Singer S, Janni W, Rack B, Widschwendter P, Lato K, Fink V, Deniz M, Friedl T, Schwentner L, Bekes I. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast Cancer Res Treat 2019; 175:627-635.
Mar 21, 2019Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
Mar 21, 2019Breast Cancer Res Treat 2019; 175:627-635
Cámara Rafael J A, Singer Susanne, Janni Wolfgang, Rack Brigitte, Widschwendter Peter, Lato Krisztian, Fink Visnja, Deniz Miriam, Friedl Thomas W P, Schwentner Lukas, Bekes Inga
Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.
Renovanz M, Hechtner M, Kohlmann K, Janko M, Nadji-Ohl M, Singer S, Ringel F, Coburger J, Hickmann A. Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out. Neurooncol Pract 2017; 5:129-138.
Oct 31, 2017Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.
Oct 31, 2017Neurooncol Pract 2017; 5:129-138
Renovanz Mirjam, Hechtner Marlene, Kohlmann Karoline, Janko Mareile, Nadji-Ohl Minou, Singer Susanne, Ringel Florian, Coburger Jan, Hickmann Anne-Katrin
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja